Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
123.80    -0.60 (-0.48%)
Bid:
123.60
Ask:
124.00
Spread: 0.40 (0.324%)
Market Cap: £301.35m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Transaction in Own Shares

25 Jan 2024 07:00

RNS Number : 8282A
PureTech Health PLC
25 January 2024
 

25 January 2024

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

24 January 2024

Number of ordinary shares purchased:

35,192

Highest price paid per share:

198.00p

Lowest price paid per share:

192.80p

Volume weighted average price paid per share:

195.69p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 18,884,863 ordinary shares in treasury and has 270,583,296 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 270,583,296 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

24/01/2024

08:29:27

815

192.8

XLON

00386861372TRLO0.1.1

24/01/2024

08:29:44

315

192.8

CHIX

00386861432TRLO0.1.1

24/01/2024

08:29:44

213

192.8

CHIX

00386861433TRLO0.1.1

24/01/2024

08:29:59

815

192.8

XLON

00386861483TRLO0.1.1

24/01/2024

08:30:43

916

192.8

XLON

00386861719TRLO0.1.1

24/01/2024

08:31:31

622

192.8

XLON

00386862022TRLO0.1.1

24/01/2024

08:34:33

515

192.8

XLON

00386862779TRLO0.1.1

24/01/2024

08:34:33

13

192.8

XLON

00386862780TRLO0.1.1

24/01/2024

08:39:41

528

192.8

XLON

00386864131TRLO0.1.1

24/01/2024

08:44:47

528

192.8

XLON

00386865524TRLO0.1.1

24/01/2024

09:32:54

6336

195

XLON

00386876245TRLO0.1.1

24/01/2024

09:34:07

173

195

CHIX

00386876729TRLO0.1.1

24/01/2024

09:34:36

96

195

CHIX

00386876791TRLO0.1.1

24/01/2024

09:37:02

2112

195.4

XLON

00386877399TRLO0.1.1

24/01/2024

09:37:08

528

194.8

BATE

00386877491TRLO0.1.1

24/01/2024

09:37:08

528

194.8

CHIX

00386877492TRLO0.1.1

24/01/2024

09:37:08

283

194.8

AQXE

00386877493TRLO0.1.1

24/01/2024

09:58:58

528

197

XLON

00386882071TRLO0.1.1

24/01/2024

10:00:28

193

197

CHIX

00386882619TRLO0.1.1

24/01/2024

10:00:28

291

197.2

CHIX

00386882620TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884053TRLO0.1.1

24/01/2024

10:08:52

1584

196.8

XLON

00386884055TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884054TRLO0.1.1

24/01/2024

10:08:52

342

196.6

TRQX

00386884056TRLO0.1.1

24/01/2024

10:16:28

1056

196.6

XLON

00386885232TRLO0.1.1

24/01/2024

10:16:28

481

196.6

XLON

00386885233TRLO0.1.1

24/01/2024

10:39:12

35

196.4

CHIX

00386889783TRLO0.1.1

24/01/2024

10:39:12

493

196.4

CHIX

00386889784TRLO0.1.1

24/01/2024

10:39:12

388

196.4

CHIX

00386889785TRLO0.1.1

24/01/2024

10:39:12

528

196.4

XLON

00386889787TRLO0.1.1

24/01/2024

10:39:12

575

196.4

XLON

00386889786TRLO0.1.1

24/01/2024

10:39:12

231

196.4

XLON

00386889788TRLO0.1.1

24/01/2024

10:39:12

148

196.4

XLON

00386889789TRLO0.1.1

24/01/2024

10:39:12

176

196.4

XLON

00386889790TRLO0.1.1

24/01/2024

10:39:13

35

196

BATE

00386889793TRLO0.1.1

24/01/2024

11:13:47

2112

196.4

XLON

00386895560TRLO0.1.1

24/01/2024

11:14:55

119

196.2

CHIX

00386895706TRLO0.1.1

24/01/2024

11:34:12

579

196.4

CHIX

00386898389TRLO0.1.1

24/01/2024

11:34:12

528

196.4

BATE

00386898390TRLO0.1.1

24/01/2024

11:34:12

2085

196.4

XLON

00386898391TRLO0.1.1

24/01/2024

11:48:28

528

196.8

XLON

00386901072TRLO0.1.1

24/01/2024

11:50:46

409

196.2

BATE

00386901394TRLO0.1.1

24/01/2024

11:50:46

2112

196.4

XLON

00386901395TRLO0.1.1

24/01/2024

12:20:02

528

197

XLON

00386906123TRLO0.1.1

24/01/2024

14:44:34

283

198

AQXE

00386943011TRLO0.1.1

24/01/2024

14:44:34

287

198

CHIX

00386943012TRLO0.1.1

24/01/2024

14:46:50

500

198

XLON

00386945228TRLO0.1.1

24/01/2024

14:46:50

154

198

CHIX

00386945227TRLO0.1.1

24/01/2024

14:46:50

52

198

TRQX

00386945229TRLO0.1.1

24/01/2024

14:46:50

28

198

XLON

00386945230TRLO0.1.1

24/01/2024

14:46:50

199

198

TRQX

00386945231TRLO0.1.1

24/01/2024

14:46:50

119

198

TRQX

00386945232TRLO0.1.1

24/01/2024

14:46:50

472

198

XLON

00386945233TRLO0.1.1

24/01/2024

14:46:50

56

198

XLON

00386945234TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945235TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945236TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFLTLIISFIS
Date   Source Headline
9th Jun 20267:00 amRNS-RPRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data
4th Jun 20265:37 pmRNSHolding(s) in Company
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 202512:05 pmRNS-RPRTC's Seaport Advances 2nd Candidate Into Clinic
4th Sep 20255:30 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.